Structure via PubChem · Public domain (PubChem)
saroglitazar
Sign in to saveSaroglitazar (INN, trade names Lipaglyn, Bilypsa) is a drug for the treatment of type 2 diabetes mellitus, dyslipidemia, NASH and NAFLD It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipide
Chemical data
- Formula
- C25H29NO4S
- Molecular weight
- 439.6 g/mol
- IUPAC name
- (2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethoxy]phenyl]propanoic acid
- SMILES
- CCO[C@@H](CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
- InChIKey
- MRWFZSLZNUJVQW-DEOSSOPVSA-N
- XLogP
- 4.9
- Polar surface area
- 86 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- carboxylic acid
- Mass
- 439.182
Show 4 more facts
- Commons category
- Saroglitazar
- canonical SMILES
- CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
- chemical formula
- C₂₅H₂₉NO₄S
- isomeric SMILES
- CCO[C@@H](CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
5 sectionsContents
- Mechanism of action
- Efficacy
- Safety
- Controversies
- References
{{Infobox drug | drug_name = | IUPAC_name = (2S)-2-Ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid | image = Saroglitazar skeletal.svg | image_class = skin-invert-image
| tradename = Lipaglyn, Bilypsa | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= C | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Approved in India | routes_of_administration = Oral
Excerpted from Wikipedia’s “saroglitazar” article, available under the CC BY-SA 4.0 licence.